J&J/Cordis’ Cypher DES threatened by supplier dispute
This article was originally published in The Gray Sheet
Executive Summary
Wyeth sues Johnson & Johnson Oct. 26 in Delaware federal court, seeking to break an agreement to supply J&J's Cordis unit with sirolimus - the drug used on the Cypher drug-eluting stent. The suit alleges material breach of contract and seeks damages, charging Cordis with failing to make "commercially reasonable" efforts to develop CCI 779 - a drug analogous to sirolimus - as required under their agreement. Cordis denies the charges. A Wyeth spokesperson told "The Gray Sheet" that "if they don't act on [the agreement] over a period of time and they languish, [they should] terminate it so that we can find another partner." Wyeth advised Cordis of the charges in writing April 14, according to the complaint. Sirolimus is marketed by Wyeth as Rapamune...
You may also be interested in...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.